Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-09-07 , DOI: 10.1128/aac.01063-21
Yinjuan Li ₁ , Lu Qi ₁ , Haihong Bai ₁ , Chunyun Sun _{2,

3,

4} , Shuping Xu ₂ , Yu Wang ₁ , Chunyu Han ₁ , Yan Li ₁ , Long Liu ₁ , Xiaoqiang Cheng ₁ , Ju Liu ₁ , Chunpu Lei ₁ , Yuanxu Tong ₁ , Mingli Sun ₁ , Lixin Yan ₂ , Weiqiu Chen ₂ , Xisheng Liu ₂ , Qing Liu ₂ , Liangzhi Xie _{2,

3,

4} , Xinghe Wang ₁

Affiliation

SCTA01 is a novel monoclonal antibody with promising prophylactic and therapeutic potential for COVID-19. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of SCTA01 in healthy adults. This was a randomized, ...

中文翻译：

针对 SARS-CoV-2 的单克隆抗体 (SCTA01) 在健康成人中的安全性、耐受性、药代动力学和免疫原性：一项随机、双盲、安慰剂对照的 I 期研究

SCTA01 是一种新型单克隆抗体，对 COVID-19 具有良好的预防和治疗潜力。本研究旨在评估 SCTA01 在健康成人中的安全性、耐受性、药代动力学 (PK) 和免疫原性。这是一个随机的、...

更新日期：2021-09-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11